AI in Dermatology Requires Physician Oversight

Artificial intelligence has entered dermatology with remarkable speed. From lesion classification tools to triage algorithms embedded in telehealth platforms, AI systems promise increased access, faster turnaround times, and greater efficiency. These are meaningful advances. But in dermatology — particularly in image-based and asynchronous care — AI must remain embedded within physician-led workflows.

Dermatology is uniquely suited to AI development because it is visually oriented. However, real-world dermatology is not simply pattern recognition. Diagnosis depends on context: incomplete histories, variable image quality, medication exposures, age-specific risk factors, and subtle morphologic distinctions that require clinical judgment beyond classification.

AI models are typically trained on curated datasets. In practice, dermatologists evaluate patient-submitted smartphone images taken in poor lighting, with limited anatomical framing, and often without reliable history. The gap between training environments and real-world use is not theoretical — it is routine.

Physician oversight is essential in three domains.

1. Real-World Image Variability

Algorithms trained on high-quality dermoscopic or standardized images may underperform when exposed to blurred, overexposed, or partially framed photographs. In asynchronous teledermatology, uncertainty is common. Human clinicians adapt to this variability, requesting additional images, modifying differential diagnoses, or escalating to in-person evaluation. AI systems must operate within oversight structures that account for these uncertainties rather than assume ideal conditions.

2. Spectrum Bias and Generalizability

Datasets often overrepresent common conditions and underrepresent atypical, rare, or pediatric presentations. Pediatric dermatology in particular presents morphology that differs from adult disease patterns. Fellowship-level training influences threshold decisions and risk assessment. Oversight ensures that model outputs are interpreted within the broader clinical spectrum rather than accepted at face value.

3. Escalation and Safety Frameworks

AI-assisted triage should never function as an endpoint. It must exist within defined escalation pathways that allow for physician review, in-person referral, or additional data collection when diagnostic confidence is limited. Oversight is not symbolic — it is structural. Without it, diagnostic certainty can be overstated, particularly in high-risk conditions.

The integration of AI into dermatology is not a question of whether, but how. Physician-led governance, validation in real-world settings, and defined escalation criteria are not barriers to innovation; they are prerequisites for safe implementation.

Artificial intelligence can support dermatologic workflows. It should not replace the clinical judgment that anchors them.